Hazna Fridella Utomo
Faculty of Medicine, Jember University, Jember, Indonesia

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

Efficacy and Safety of Mesenchymal Stem Cell Therapy in Chronic Limb-Threatening Ischemia: A Meta-analysis of Randomized Controlled Trials Nabil Athoillah; Arya Marganda Simanjuntak; Mitsla Chusnica Aulia As’Ar; Dimas Widyadhana Bhanu Aryasatya; Lunggita Arabela Sugiarto; Hazna Fridella Utomo; Meutia Citra Aisya; Kevin Sanjaya Listiono; Ayu Diajeng Sekar Negari; Yusfik Helmi Hidayat; Aditha Satria Maulana
Jurnal Kardiologi Indonesia Online First
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.1990

Abstract

Background: Chronic Limb-Threatening Ischemia (CLTI) represents the terminal stage of peripheral artery disease, carrying substantial morbidity and mortality. Despite various therapeutic strategies, clinical outcomes remain unsatisfactory, highlighting the urgent need for novel treatments. While Mesenchymal Stem Cells (MSCs) show promise at the cellular level, human studies are limited, preventing generalizable conclusions at this time. This study aimed to systematically assess the efficacy and safety of MSCs implantation in CLTI. Methods: PRISMA 2020-guided meta-analysis of intervention. Various databases were searched using keywords based of the PICOS framework. The PICOS framework guided our approach: Patients (CLTI), Intervention (MSCs), Comparison (Placebo OR Control), Outcome (Amputation, Ulcer Healing Rate, Rest Pain Change, Ankle-Brachial Index, Adverse Effect), and Study (Randomized Controlled Trial [RCT]). Statistical analysis was performed using Review Manager (RevMan 5.4.1) and RStudio (R.4.4.3). An Independent Risk-of-Bias 2 (RoB2) risk of bias assessment was performed. Results: Seven RCTs were included with a total of 270 patients. Meta-analysis showed that MSCs were more effective than the control group on suppressing the amputation rate (Odds Ratio [OR] = 0.40, 95% Confidence Interval [CI] = 0.17–0.95, p = 0.04). Ulcer healing rate was significantly higher in the MSCs therapy group compared to the control group (OR = 9.79, 95% CI = 2.59–36.98, p = 0.0008). Moreover, MSCs therapy markedly improved clinical outcomes, including rest pain score (Mean Difference [MD] = –1.88, 95% CI = –2.93 to –0.84, p = 0.0004) and ankle-brachial index (MD = 0.16, 95% CI = 0.09–0.22, p < 0.00001). Interestingly, MSCs therapy showed an excellent safety profile, with negligible gastrointestinal-hepatobiliary events and only 4% mild infections or musculoskeletal effects. Conclusion: This review shows that MSCs therapy offers a transformative approach for CLTI, significantly improving limb outcomes and perfusion while maintaining an excellent safety profile.